We are live on ! Find out more
INSY

Insys Therapeutics, Inc.
INSY

Delisted

INSY was delisted on the 18th of June, 2019.

Back to rankings

111 hedge funds and large institutions have $539M invested in Insys Therapeutics, Inc. in 2014 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 40 increasing their positions, 32 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

75% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 16

53% more capital invested

Capital invested by funds: $352M → $539M (+$187M)

25% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 32

12% more funds holding

Funds holding: 99 → 111 (+12)

0% more call options, than puts

Call options by funds: $8.81M | Put options by funds: $8.8M

Holders
111
Holders Change
+12
Holders Change %
+12.12%
% of All Funds
3.22%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
28
Increased
40
Reduced
32
Closed
16
Calls
$8.81M
Puts
$8.8M
Net Calls
+$15K
Net Calls Change
+$1.66M

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$23.1M
2
Millennium Management
Millennium Management
New York
+$20.7M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$15.9M
4
EAM
EverPoint Asset Management
Connecticut
+$14.9M
5
JHIU
Janus Henderson Investors US
Colorado
+$10M

Top Sellers

Rank Fund Capital Flow
1
BA
BlackRock Advisors
Delaware
-$10.4M
2
BTP
Bloom Tree Partners
New York
-$7.85M
3
BG
BlackRock Group
United Kingdom
-$6.36M
4
PP
PDT Partners
New York
-$5.22M
5
Morgan Stanley
Morgan Stanley
New York
-$3.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
American Century Companies
26
American Century Companies
Missouri
$4.01M +$1.43M +90,828 +78%
QBFM
27
QS Batterymarch Financial Management
New York
$3.97M -$342K -21,800 -10%
GC
28
Guggenheim Capital
Illinois
$3.35M -$371K -23,596 -12%
SFM
29
Systematic Financial Management
New Jersey
$3.18M +$11K +700 +0.4%
CS
30
Credit Suisse
Switzerland
$2.95M +$1.9M +120,822 +383%
PI
31
Putnam Investments
Massachusetts
$2.93M +$33.6K +2,138 +1%
JGC
32
J. Goldman & Co
New York
$2.87M +$813K +51,750 +54%
New York State Common Retirement Fund
33
New York State Common Retirement Fund
New York
$2.77M – – –
ACM
34
Argent Capital Management
Missouri
$2.77M +$2.24M +142,600 New
GACM
35
Green Arrow Capital Management
New York
$2.71M -$446K -28,400 -17%
BA
36
BlackRock Advisors
Delaware
$2.67M -$10.4M -661,472 -83%
Geode Capital Management
37
Geode Capital Management
Massachusetts
$2.23M +$364K +23,164 +25%
B
38
Baird
Wisconsin
$2.08M +$1.68M +107,026 New
Bank of New York Mellon
39
Bank of New York Mellon
New York
$2.06M +$253K +16,108 +18%
M&T Bank
40
M&T Bank
New York
$2M +$1.62M +103,268 New
Adage Capital Partners
41
Adage Capital Partners
Massachusetts
$1.99M +$1.61M +102,614 New
ACM
42
Atika Capital Management
New York
$1.98M +$1.6M +102,000 New
Morgan Stanley
43
Morgan Stanley
New York
$1.84M -$3.52M -224,000 -70%
ARTA
44
A.R.T. Advisors
New York
$1.66M +$1.34M +85,514 New
GH
45
GAM Holding
Switzerland
$1.63M – – –
AQR Capital Management
46
AQR Capital Management
Connecticut
$1.54M +$9.42K +600 +0.8%
TCIM
47
TIAA CREF Investment Management
New York
$1.43M -$50.8K -3,238 -4%
AI
48
Analytic Investors
California
$1.37M -$425K -27,064 -28%
WMSA
49
Weiss Multi-Strategy Advisers
New York
$1.36M +$157K +10,000 +17%
Wellington Management Group
50
Wellington Management Group
Massachusetts
$1.27M +$1.03M +65,400 New
1
2
3 4 5

INSY Hedge Fund Activity: Q3 2014 in Review

111 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q3 2014, worth a combined $539M — up 53% from $352M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new INSY positions and 16 closed out — a net gain of 12 holders — while 40 added to existing stakes and 32 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $23.1M. The largest seller was BlackRock Advisors, cutting an estimated $10.4M.

  • 111 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q3 2014, up from 99 in Q2 2014.
  • Funds reported $539M of Insys Therapeutics, Inc. stock for Q3 2014, up 53% quarter-over-quarter.
  • 28 funds opened new Insys Therapeutics, Inc. positions in Q3 2014 and 16 closed out, a net change of +12 holders.
  • The largest Insys Therapeutics, Inc. buyer in Q3 2014 was OrbiMed, an estimated $23.1M added.
  • The largest Insys Therapeutics, Inc. seller in Q3 2014 was BlackRock Advisors, an estimated $10.4M sold.

Based on aggregated 13F filings for Q3 2014.